417 related articles for article (PubMed ID: 3612533)
21. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
[TBL] [Abstract][Full Text] [Related]
22. Effect of specific antagonists on PAF-induced platelet aggregation and release of plasminogen activator.
Hofmann B; Ostermann G; Hoffmann A; Klöcking HP; Kertscher HP
Biomed Biochim Acta; 1988; 47(10-11):S157-60. PubMed ID: 3248103
[TBL] [Abstract][Full Text] [Related]
23. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation.
Chang GT; Kang SK; Kim JH; Chung KH; Chang YC; Kim CH
J Ethnopharmacol; 2005 Dec; 102(3):430-9. PubMed ID: 16125889
[TBL] [Abstract][Full Text] [Related]
25. [Effects of ketotifen on rabbit platelet aggregation and platelet activating factor formation from rat neutrophils].
Wang XD; Bian RL
Zhongguo Yao Li Xue Bao; 1990 Nov; 11(6):524-7. PubMed ID: 2130617
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
27. Platelet-activating factor (PAF) antagonistic actions of two new analogs of tetrahydrofurans.
Tsao PS; Stahl GA; Lefer AM; Salvino J; Pietranico S; Nicolaou KC
J Lipid Mediat; 1989; 1(3):189-99. PubMed ID: 2519893
[TBL] [Abstract][Full Text] [Related]
28. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC
J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
[TBL] [Abstract][Full Text] [Related]
29. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
Yue TL; Rabinovici R; Farhat M; Feuerstein G
J Lipid Mediat; 1991; 3(1):13-26. PubMed ID: 1768837
[TBL] [Abstract][Full Text] [Related]
31. Effects of plumbagin on platelet aggregation and platelet-neutrophil interactions.
Shen Z; Dong Z; Cheng P; Li L; Chen Z; Liu J
Planta Med; 2003 Jul; 69(7):605-9. PubMed ID: 12898414
[TBL] [Abstract][Full Text] [Related]
32. Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
Takatani M; Yoshioka Y; Tasaka A; Terashita Z; Imura Y; Nishikawa K; Tsushima S
J Med Chem; 1989 Jan; 32(1):56-64. PubMed ID: 2909744
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
Fernández-Gallardo S; Ortega MP; Priego JG; de Casa-Juana MF; Sunkel C; Sánchez Crespo M
J Pharmacol Exp Ther; 1990 Oct; 255(1):34-9. PubMed ID: 2170626
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
Wu MS; Biftu T; Doebber TW
J Pharmacol Exp Ther; 1986 Dec; 239(3):841-5. PubMed ID: 3795043
[TBL] [Abstract][Full Text] [Related]
35. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
36. Piperbetol, methylpiperbetol, piperol A and piperol B: a new series of highly specific PAF receptor antagonists from Piper betle.
Zeng HW; Jiang YY; Cai DG; Bian J; Long K; Chen ZL
Planta Med; 1997 Aug; 63(4):296-8. PubMed ID: 9270371
[TBL] [Abstract][Full Text] [Related]
37. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.
Doebber TW; Wu MS; Biftu T
J Immunol; 1986 Jun; 136(12):4659-68. PubMed ID: 3011900
[TBL] [Abstract][Full Text] [Related]
38. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects.
Kamei C; Mio M; Kitazumi K; Tsujimoto S; Yoshida T; Adachi Y; Tasaka K
Immunopharmacol Immunotoxicol; 1992; 14(1-2):207-18. PubMed ID: 1350791
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological profile of epiyangambin: a furofuran lignan with PAF antagonist activity.
Castro-Faria-Neto HC; Martins MA; Silva PM; Bozza PT; Cruz HN; de Queiroz-Paulo M; Kaplan MA; Cordeiro RS
J Lipid Mediat; 1993 May; 7(1):1-9. PubMed ID: 8358020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
